

Your capital is at risk. Past performance is not a guide to future returns. The following update is based on a representative portfolio. As such, stock examples may not be held in every client portfolio, and performance may differ.

This transcript was generated by AI.

Bill Chater: Discovery has a single mission: to identify underappreciated innovators early, support them for the long term, but continually reassess their merit relative to the next generation of great businesses. We manage the strategy to deliver long-term returns through operational growth. Now, we recognise the need to repair the long-term track record and, as we've discussed in previous updates, this is the team's core focus.

Overall though, 2025 has been a rewarding year with robust absolute returns. Disappointingly though, a weak fourth quarter has dragged the annual relative number slightly behind the benchmark. Now, we've always guided clients to expect performance over short periods such as quarters to be volatile, both to the upside as we saw in the third quarter of 2025, but also to the downside as we've seen this quarter.

So while we won't overreact to a difficult quarter, let's examine the recent performance drivers, but use these to illustrate our confidence in the portfolio going into 2026 and beyond.

First, after a prolonged rally, the AI market complex experienced an evaluation reset in November, with investors confronting questions about the growth required to deliver returns above the already rich premiums. And this prompted a shift away from US tech to more traditionally defensive or cyclical areas, and several of our names have been caught in this rotation.

But we've not seen anything to dampen our long-term bullishness on AI's transformative potential. Now, to capture this for clients, we're focusing on the bottlenecks of the AI value chain, where companies can extract the greatest value, and then identifying those whose growth is occurring here and now. The physical infrastructure required to build and run AI data centres is a clear example.

Despite the price pressure on holdings like Iron and Astera Labs, their rapid growth illustrates the need and demand for these services.

Second, heading into 2026, we're again at a point of uncertainty surrounding US monetary, fiscal and trade policies. Despite US interest rates being cut again in December, the longer end of yields actually crept slightly higher, dampening market enthusiasm for long-term growth opportunities.

And this contributed to the portfolio's valuation being compressed, with aggregate price-to-sales metrics declining. It's important, though, to remember that the political policy cycle moves quickly, especially at the moment. It's barely 12 months since the Trump election rally.

It's less than nine months since the volatility of Liberation Day. But this is why we adhere to our process of identifying and thoroughly understanding the best companies within our universe, then trusting capable management teams to navigate turbulence and relying on the long-term correlation between operational

growth and share price performance. In that regard, the portfolio is in strong health. It's forecast to grow sales and earnings at three times the rate of the index over the coming year.

Third, we saw some price pressure on some of the portfolio's larger names. The law enforcement technology company Axon saw its price fall after its latest earnings report revealed compressed margins due to tariffs on imported input materials.

While, despite its latest earnings delivering a beat and guidance rise, Alnylam, the RNA Pharmaceuticals company, saw some profit-taking following a strong run this year. We retain firm conviction in both of these holdings. American Superconductor, the grid systems and resiliency business, experienced a pronounced drawdown following its latest earnings release.

Despite reporting strong growth, this failed to meet investors' expectations. We reviewed the position this quarter, though, following a meeting with the CEO, and came away with the conclusion that given the need for US grid modernisation, and AMSC broadening from being a component provider to one which offers solutions, we can build conviction in a long-term 25 per cent per annum growth trajectory.

Given the price declines, this scenario is absolutely not reflected in the market valuation. Now, to be clear, despite this quarter's weak performance, several of our holdings delivered exceptional returns. Our healthcare names were broadly strong.

Garden Health, the cancer diagnostics business, and Tandem Diabetes, the insulin pump manufacturer, both rallied sharply on impressive quarterly results, while Exact Sciences and Confluent both appreciated on the news that trade buyers would acquire them.

Finally, the end of 2025 marks 12 months since we introduced meaningful process enhancements. These, along with the enthusiasm of several new team members, have led to a repositioning of nearly half of the portfolio over the last year. Now, we expect this rate of turnover to moderate.

Nevertheless, we're excited by the pace and the quality of idea generation, the competition for capital is at its highest level for years. And the portfolio is now exposed to companies at the heart of today's most important structural growth themes, spanning those that meet the current need for security and resource sovereignty to those which are powering the future of compute and unlocking genomic secrets.

It's our excitement about these companies and their potential influence over the coming decade that gives us the confidence to say to you that despite this quarter's volatility, the prospects for the Discovery portfolio have seldom been so bright. Thank you for watching today. Goodbye.

Discovery (representing Global Discovery and Worldwide Discovery strategies)

Annual past performance to December each year (%)

	2021	2022	2023	2024	2025
Worldwide Discovery Composite* (gross)	-21.7	-40.9	4.1	-1.5	17.4
Worldwide Discovery Composite (net)	-22.3	-41.4	3.4	-2.2	16.6
MSCI ACWI Small Cap Index	16.5	-18.3	17.4	8.2	20.3

Annualised returns to 31 December 2025 (%)

	1 year	5 years	10 years	Since Inception*
Worldwide Discovery Composite (gross)	17.4	-11.0	N/A	6.3
Worldwide Discovery Composite (net)	16.6	-11.7	N/A	5.5
MSCI ACWI Small Cap Index	20.3	7.8	N/A	8.9

*Inception date: 30 June 2017.

Source: Revolution, MSCI. US dollars. Returns have been calculated by reducing the gross return by the highest annual management fee for the composite. 1 year figures are not annualised.

Past performance is not a guide to future returns.

Legal notice: MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indexes or any securities or financial products. This report is not approved, endorsed, reviewed or produced by MSCI. None of the MSCI data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.

Risk Factors

The views expressed should not be considered as advice or a recommendation to buy, sell or hold a particular investment. They reflect opinion and should not be taken as statements of fact nor should any reliance be placed on them when making investment decisions.

This communication was produced and approved in January 2026 and has not been updated subsequently. It represents views held at the time of writing and may not reflect current thinking.

Potential for Profit and Loss

All investment strategies have the potential for profit and loss, your or your clients' capital may be at risk. Past performance is not a guide to future returns.

This communication contains information on investments which does not constitute independent research. Accordingly, it is not subject to the protections afforded to independent research, but is classified as advertising under Art 68 of the Financial Services Act ('FinsA') and Baillie Gifford and its staff may have dealt in the investments concerned.

All information is sourced from Baillie Gifford & Co and is current unless otherwise stated.

The images used in this communication are for illustrative purposes only.

Important Information

Baillie Gifford & Co and Baillie Gifford & Co Limited are authorised and regulated by the Financial Conduct Authority (FCA). Baillie Gifford & Co Limited is an Authorised Corporate Director of OEICs.

Baillie Gifford Overseas Limited provides investment management and advisory services to non-UK Professional/Institutional clients only. Baillie Gifford Overseas Limited is wholly owned by Baillie Gifford & Co. Baillie Gifford & Co and Baillie Gifford Overseas Limited are authorised and regulated by the FCA in the UK.

Persons resident or domiciled outside the UK should consult with their professional advisers as to whether they require any governmental or other consents in order to enable them to invest, and with their tax advisers for advice relevant to their own particular circumstances.

Financial Intermediaries

This communication is suitable for use of financial intermediaries. Financial intermediaries are solely responsible for any further distribution and Baillie Gifford takes no responsibility for the reliance on this document by any other person who did not receive this document directly from Baillie Gifford.

Europe

Baillie Gifford Investment Management (Europe) Ltd (BGE) is authorised by the Central Bank of Ireland as an AIFM under the AIFM Regulations and as a UCITS management company under the UCITS Regulation. BGE also has regulatory permissions to perform Individual Portfolio Management activities. BGE provides investment management and advisory services to European (excluding UK) **segregated** clients. BGE has been appointed as UCITS management company to the following UCITS umbrella company; Baillie Gifford Worldwide Funds plc. BGE is a wholly owned subsidiary of Baillie Gifford Overseas Limited, which is wholly owned by Baillie Gifford & Co. Baillie Gifford Overseas Limited and Baillie Gifford & Co are authorised and regulated in the UK by the Financial Conduct Authority.

Hong Kong

Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港)有限公司 is wholly owned by Baillie Gifford Overseas Limited and holds a Type 1 license from the Securities & Futures Commission of Hong Kong to market and distribute Baillie Gifford's range of collective investment schemes to professional investors in Hong Kong. Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港)有限公司 can be contacted at Suites 2713-2715, Two International Finance Centre, 8 Finance Street, Central, Hong Kong. Telephone +852 3756 5700.

South Korea

Baillie Gifford Overseas Limited is licensed with the Financial Services Commission in South Korea as a cross border Discretionary Investment Manager and Non-discretionary Investment Adviser.

Japan

Mitsubishi UFJ Baillie Gifford Asset Management Limited ('MUBGAM') is a joint venture company between Mitsubishi UFJ Trust & Banking Corporation and Baillie Gifford Overseas Limited. MUBGAM is authorised and regulated by the Financial Conduct Authority.

Australia

Baillie Gifford Overseas Limited (ARBN 118 567 178) is registered as a foreign company under the Corporations Act 2001 (Cth) and holds Foreign Australian Financial Services Licence No 528911. This material is provided to you on the basis that you are a "wholesale client" within the meaning of section 761G of the Corporations Act 2001 (Cth) ("Corporations Act"). Please advise Baillie Gifford Overseas Limited immediately if you are not a wholesale client. In no circumstances may this material be made available to a "retail client" within the meaning of section 761G of the Corporations Act.

This material contains general information only. It does not take into account any person's objectives, financial situation or needs.

South Africa

Baillie Gifford Overseas Limited is registered as a Foreign Financial Services Provider with the Financial Sector Conduct Authority in South Africa.

North America

Baillie Gifford International LLC is wholly owned by Baillie Gifford Overseas Limited; it was formed in Delaware in 2005 and is registered with the SEC. It is the legal entity through which Baillie Gifford Overseas Limited provides client service and marketing functions in North America. Baillie Gifford Overseas Limited is registered with the SEC in the United States of America.

The Manager is not resident in Canada, its head office and principal place of business is in Edinburgh, Scotland. Baillie Gifford Overseas Limited is regulated in Canada as a portfolio manager and exempt market dealer with the Ontario Securities Commission ('OSC'). Its portfolio manager licence is currently passported into Alberta, Quebec, Saskatchewan, Manitoba and Newfoundland & Labrador whereas the exempt market dealer licence is passported across all Canadian provinces and territories.

Israel

Baillie Gifford Overseas Limited is not licensed under Israel's Regulation of Investment Advising, Investment Marketing and Portfolio Management Law, 5755-1995 (the Advice Law) and does not carry insurance pursuant to the Advice Law. This material is only intended for those categories of Israeli residents who are qualified clients listed on the First Addendum to the Advice Law.

Singapore

Baillie Gifford Asia (Singapore) Private Limited is wholly owned by Baillie Gifford Overseas Limited and is regulated by the Monetary Authority of Singapore as a holder of a capital markets services licence to conduct fund management activities for institutional investors and accredited investors in Singapore. Baillie Gifford Overseas Limited, as a foreign related corporation of Baillie Gifford Asia (Singapore) Private Limited, has entered into a cross-border business arrangement with Baillie Gifford Asia (Singapore) Private Limited, and shall be relying upon the exemption under regulation 4 of the Securities and Futures (Exemption for Cross-Border Arrangements) (Foreign Related Corporations) Regulations 2021 which enables both Baillie Gifford Overseas Limited and Baillie Gifford Asia (Singapore) Private Limited to market the full range of segregated mandate services to institutional investors and accredited investors in Singapore.